JMHLY 0HLMA.L 0FNV.TO -0.02DFY.TO 1.12AGF.B.TO -0.18CDR.TO -0.07BLX -0.36KINS 0.09
Bristol Myers Squibb (BMY)

NYSE:BMY

Bristol Myers Squibb (BMY)

60.16
-0.58 (0.95%)
as of Jul 20, 2026, 8:00:00 pm Market Open.
160 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJul 20, 2026, 12:00 am

This summary was created by AI, based on 7 opinions in the last 12 months.

Bristol Myers Squibb (BMY-N) has garnered mixed reviews from experts, highlighting both its potential and setbacks. While some analysts praise its solid dividend yield, promising drug pipeline, and recent earnings performance that exceeded expectations, others express concerns regarding the disappointing sales of its Cobenfy drug. Recent financial results indicate a modest sales growth of 3% and a significant 18% increase in its growth portfolio, albeit with a downturn in legacy drugs. Additionally, the company's management has raised its revenue guidance for 2025, which provides a glimmer of optimism for future performance. Overall, there is cautious optimism about a possible rebound if the growth portfolio continues to outperform older products.

consensus icon
Consensus
Mixed
valuation icon
Valuation
Undervalued
review icon
Similar
EliLilly, LLY
DON'T BUY

Bristol Myers Squibb(BMY)

May 27, 2002
New drug failed and generic drug companies getting into their products. Market share will probably shrink.
Photo of Paul O'NeilPaul O'NeilUnlock Rating
$30.40

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Bristol Myers Squibb(BMY)

May 23, 2002
Decent upside potential. Close to a decent technical support. Relatively cheap.
Photo of Ross HealyRoss HealyUnlock Rating
$30.92

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Bristol Myers Squibb(BMY)

May 09, 2002
(Was a top pick on Apr 4 down 11%) Still likes.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$28.30

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Bristol Myers Squibb(BMY)

Apr 22, 2002
Very reasonable valuation. Patents are coming off. Prefers Pfizer.
Photo of Michelle CalpinMichelle CalpinUnlock Rating
$31.73

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Bristol Myers Squibb(BMY)

Apr 04, 2002
Has had some negative occurances. At a good price.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$32.15

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
BUY

Bristol Myers Squibb(BMY)

Feb 13, 2002
18 X next years earnings makes it very attractive.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$46.17

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Bristol Myers Squibb(BMY)

Feb 06, 2002
(Was a top pick on Dec 17 up 15%) At a historic low.
Photo of Bob StodgellBob StodgellUnlock Rating
$42.80

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Bristol Myers Squibb(BMY)

Jan 30, 2002
Broke through a technical base. Generics are giving some tough competition.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$44.93

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
TOP PICK

Bristol Myers Squibb(BMY)

Dec 17, 2001
Restructured. In a temporary downturn.
Photo of Bob StodgellBob StodgellUnlock Rating
$50.15

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
BUY

Bristol Myers Squibb(BMY)

Jun 05, 2001
Good upside potential.
Photo of Ross HealyRoss HealyUnlock Rating
$57.91

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Bristol Myers Squibb(BMY)

Apr 25, 2001
Not a fan at this time. Patent expiries coming up. Prefers Pfizer.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$56.86

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
Showing 211 to 221 of 221 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

WSP.TO -3.18$178.17
MURGF 0$592.945
MSFT 8.47$402.29
UN -0.951$25.2741
TIH.TO -7.66$228.1

Today's Top Picks

JMHLY 0$63.05
HLMA.L 0$2527
FNV.TO -0.02$281.28
DFY.TO 1.12$79.4
AGF.B.TO -0.18$22.71

Popular Articles

Latest Sell Signals

CNQ.TO 0.46$61.88
SNDK 36.13$1390.95
CLF -0.3$8.98
BNS.TO -2.87$122.41
LOGI -1.05$101.78

Most Recent Experts

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

David Driscoll

David Driscoll

Liberty International Investment Management Inc

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like